Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06833073 | RECRUITING | Urinary Bladder Neoplasms

A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Sponsor:

Merck Sharp & Dohme LLC

Brief Summary:

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding V940, the study treatment, to standard treatment can help treat HR NMIBC. V940 is designed to help a person's immune system attack their specific cancer. The goals of this study are to learn: * If people who receive V940 with BCG live longer without the cancer growing, spreading, or coming back, or dying from any cause, compared to people who receive BCG alone * If more people who receive V940 with BCG have their cancer go away (complete response), compared to people who receive BCG alone * How many people who receive V940 without BCG have their cancer go away

Condition or disease

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Carcinoma in Situ

Intervention/treatment

V940

BCG

Phase

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 308 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
Actual Study Start Date : 2025-03-11
Estimated Primary Completion Date : 2031-09-03
Estimated Study Completion Date : 2031-09-03

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • The main inclusion criteria include but are not limited to the following
    • - Is an individual whose most recent TURBT was performed within 12 weeks before randomization/allocation and showed BICR-confirmed high-risk NMIBC histology
    • BCG Arms
      • * Has high-risk non-muscle invasive (HG Ta, T1, and/or CIS) UC of the bladder
      • * Is BCG-naïve defined as either having never received BCG or having received BCG more than 2 years before high-risk NMIBC recurrence. Recurrence must be at least 24 months from the last exposure to BCG with evidence of complete response during the 2-year period post BCG
      • V940 Monotherapy Arm
        • * Has CIS +/-papillary non-muscle invasive UC of the bladder
        • * Is ineligible for, or refusing, any IVESIC therapy
        • * Is either BCG-naïve (as defined above) or BCG-exposed but did not receive protocol-specified minimum dosing of BCG and experienced recurrence of high-risk NMIBC within 2 years of the last dose of BCG
        • * Human immunodeficiency virus (HIV)-infected individuals must have well controlled HIV on antiretroviral therapy (ART)
        Exclusion Criteria
        • The main exclusion criteria include but are not limited to the following
          • * Has a history of or concurrent locally-advanced (ie, T2, T3, T4) or metastatic UC
          • * Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or a history of extravesical non-muscle invasive UC that recurred within the last 2 years, with certain exceptions
          • * Has a known additional malignancy that is progressing or has required active treatment within the last 3 years
          • * Has had a myocardial infarction within 6 months of randomization/allocation
          • * Has received any systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation
          • * Has received prior treatment with a cancer vaccine
          • * Has immunodeficiency or is receiving chronic systemic steroid therapy
          • * Has active autoimmune disease that has required systemic treatment in the last 2 years
          • * Has any contraindication to IV contrast and gadolinium or is otherwise unable to have imaging with either computerized tomography urogram (CTU) or Magnetic resonance urography (MRU)
          • BCG Arms
            • * Has current active tuberculosis
            • * Has a known history of HIV infection
            • V940 Monotherapy Arm
              • - HIV-infected individuals with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Location Details

NCT06833073

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Michael G Oefelein Clinical Trials ( Site 0138)

Bakersfield, California, United States, 93301

RECRUITING

United States, California

Los Alamitos Hematology Oncology Medical Group ( Site 0141)

The Alamitos, California, United States, 90720

RECRUITING

United States, California

Genesis Healthcare-Torrance ( Site 0140)

Torrance, California, United States, 90503

RECRUITING

United States, California

Genesis Research LLC ( Site 0118)

Torrance, California, United States, 90505

RECRUITING

United States, Florida

Urological Research Network ( Site 0133)

Hialeah, Florida, United States, 33016

RECRUITING

United States, Texas

Urology Austin, PLLC ( Site 0109)

Austin, Texas, United States, 78759

RECRUITING

Argentina, CABA

LOBANÉS SIRIUM HOSPITAL CHANGE ASSOCIATION (SITE 0303)

Buenos Aires, CABA, Argentina, C1419AHN

RECRUITING

Australia, New South Wales

Macquarie University ( Site 1801)

Macquarie University, New South Wales, Australia, 2109